Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

ACT-1016-0707

Copy Product Info
😃Good
Catalog No. T85589Cas No. 2569467-78-1
Alias LPA1 receptor antagonist 2

ACT-1016-0707 is a potent, selective, and insurmountable lysophosphatidic acid receptor 1 (LPA1) antagonist,ACT-1016-0707 demonstrates pronounced antifibrotic and anti-inflammatory activities in experimental models. ACT-1016-0707 has been studied extensively in vitro and in vivo lung fibrosis models, where it reduces pathological fibrotic progression, thereby representing a candidate compound for research into fibrotic lung diseases.

ACT-1016-0707

ACT-1016-0707

Copy Product Info
😃Good
Purity: 99.90%
Catalog No. T85589Alias LPA1 receptor antagonist 2Cas No. 2569467-78-1
ACT-1016-0707 is a potent, selective, and insurmountable lysophosphatidic acid receptor 1 (LPA1) antagonist,ACT-1016-0707 demonstrates pronounced antifibrotic and anti-inflammatory activities in experimental models. ACT-1016-0707 has been studied extensively in vitro and in vivo lung fibrosis models, where it reduces pathological fibrotic progression, thereby representing a candidate compound for research into fibrotic lung diseases.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$78-In Stock
5 mg$158-In Stock
10 mg$226-In Stock
25 mg$397-In Stock
50 mg$569-In Stock
100 mg$786-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.90%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
ACT-1016-0707 is a potent, selective, and insurmountable lysophosphatidic acid receptor 1 (LPA1) antagonist,ACT-1016-0707 demonstrates pronounced antifibrotic and anti-inflammatory activities in experimental models. ACT-1016-0707 has been studied extensively in vitro and in vivo lung fibrosis models, where it reduces pathological fibrotic progression, thereby representing a candidate compound for research into fibrotic lung diseases.
SynonymsLPA1 receptor antagonist 2
Chemical Properties
Molecular Weight438.93
FormulaC19H23ClN4O4S
Cas No.2569467-78-1
SmilesC(NC=1C(OC)=CC(Cl)=NC1)(=O)C2(CN(S(N)(=O)=O)C2)C3=C(C(C)C)C=CC=C3
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 80 mg/mL (182.26 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.2783 mL11.3913 mL22.7827 mL113.9134 mL
5 mM0.4557 mL2.2783 mL4.5565 mL22.7827 mL
10 mM0.2278 mL1.1391 mL2.2783 mL11.3913 mL
20 mM0.1139 mL0.5696 mL1.1391 mL5.6957 mL
50 mM0.0456 mL0.2278 mL0.4557 mL2.2783 mL
100 mM0.0228 mL0.1139 mL0.2278 mL1.1391 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy ACT-1016-0707 | purchase ACT-1016-0707 | ACT-1016-0707 cost | order ACT-1016-0707 | ACT-1016-0707 chemical structure | ACT-1016-0707 formula | ACT-1016-0707 molecular weight